1. Badali H, Alian S, Fakhim H, Falahatinejad M, Moradi A, Mohammad Davoudi M, et al. Cryptococcal meningitis due to Cryptococcus neoformans genotype AFLP1/VNI in Iran: a review of the literature. Mycoses. 2015; 58(12):689-93.
2. Bandalizadeh Z, Seyedmousavi M, Melchers WJ, Fami Zaghrami M, Mostaed Rostami AA, Shokohi T. Cryptococcus and cryptococcosis: updates on pathogenesis, diagnosis and treatment strategies for HIV infected patients. J Mazandaran Univ Med Sci. 2018; 28(163):144-72.
3. Rezai MS, Khotael G, Kheirkhah M, Hedayat T, Geramishoar M, Mahjoub F. Cryptococcosis and deficiency of interleukin12r. Pediatr Infect Dis J. 2008; 27(7):673.
4. Pakshir K, Fakhim H, Vaezi A, Meis JF, Mahmoodi M, Zomorodian K, et al. Molecular epidemiology of environmental Cryptococcus species isolates based on amplified fragment length polymorphism. J Mycol Med. 2018; 28(4):599-605.
5. Kambugu A, Meya DB, Rhein J, O'Brien M, Janoff EN, Ronald AR, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008; 46(11):1694-701.
6. Abassi M, Boulware DR, Rhein J. Cryptococcal meningitis: diagnosis and management update. Curr Trop Med Rep. 2015; 2(2):90-9.
7. Bandalizadeh Z, Shokohi T, Badali H, Abastabar M, Babamahmoudi F, Davoodi L, et al. Molecular epidemiology and antifungal susceptibility profiles of clinical Cryptococcus neoformans/Cryptococcus gattii species complex. J Med Microbiol. 2020; 69(1):72-81.
8. Pescador MR, Thapa B. Meningitis, cryptococcal. Treasure Island (FL): StatPearls Publishing; 2020.
9. Bicanic T, Harrison TS. Cryptococcal meningitis. Br Med Bull. 2005; 72(1):99-118.
10. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000; 30(4):710-8.
11. Hedayati MT, Taghizadeh Armaki M, Yazdani Charati J, Hedayati N, Seyedmousavi S, Denning DW. Burden of fungal infections in Iran. Journal of infection in developing countries. 2018; 12(10):910-8.
12. Lee YC, Wang JT, Sun HY, Chen YC. Comparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection. J Microbiol Immunol Infect. 2011; 44(5):338-45.
13. Ghasemian R, Najafi N, Shokohi T. Cryptococcal meningitis relapse in an immunocompetent patient. Arch Clin Infect Dis. 2011; 6(1):51-5.
14. Liao CH, Chi CY, Wang YJ, Tseng SW, Chou CH, Ho CM, et al. Different presentations and outcomes between HIV-infected and HIV-uninfected patients with Cryptococcal meningitis. J Microbiol Immunol Infect. 2012; 45(4):296-304.
15. Zhang C, Tan Z, Tian F. Impaired consciousness and decreased glucose concentration of CSF as prognostic factors in immunocompetent patients with cryptococcal meningitis. BMC Infect Dis. 2020; 20(1):69.
16. Liu Y, Kang M, Wu SY, Ma Y, Chen ZX, Xie Y, et al. Different characteristics of cryptococcal meningitis between HIV-infected and HIV-uninfected patients in the Southwest of China. Med Mycol. 2017; 55(3):255-61.
17. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010; 50(3):291-322.